Breakthrough Marker Identified as the Achilles’ Heel of Highly Aggressive Metastatic Colorectal Cancer

In a groundbreaking advancement for colorectal cancer therapy, a collaborative team from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute has pinpointed a pivotal biomarker that delineates the most lethal subpopulations of colorectal cancer cells. Their recently published study in Nature offers a comprehensive analysis demonstrating that TROP2, a cell surface glycoprotein, critically identifies the metastasis-initiating cells within colorectal tumors. Even more compelling is the revelation that leveraging existing TROP2-targeted antibody-drug conjugates, already approved for treating other cancer types, can markedly enhance treatment efficacy when combined with conventional chemotherapy regimens.

Colorectal cancer remains a formidable challenge in oncology, ranking among the leading causes of cancer-related mortality worldwide. The prognosis sharply diminishes once the cancer metastasizes, primarily due to the capacity of cancer cells to adapt dynamically, evading therapeutic assaults through a phenomenon known as cellular plasticity. This ability allows tumor cells to switch their phenotypic states and develop resistance against diverse treatment modalities, substantially complicating clinical management and contributing to high relapse rates.

The investigative team, headed by René Jackstadt, embarked on an exhaustive genomic and transcriptomic evaluation of colorectal cancer patient datasets to understand the molecular underpinnings linked to aggressive tumor behavior. Their analysis uncovered a conspicuous enrichment of TROP2 expression in tumor cells with heightened metastatic potential and resistance to treatment. This correlation was striking, positioning TROP2 as a robust prognostic biomarker predicting recurrence and poor patient outcomes.

Intriguingly, functional assays revealed that TROP2-expressing colorectal cancer cells embody traits reminiscent of embryonic intestinal cells, referred to as a “fetal-like” cell state. This state, characterized by enhanced plasticity and stemness properties, has been implicated in facilitating metastasis and therapeutic escape in various malignancies. The identification of TROP2 as a defining marker for these cells reshapes our understanding of tumor hierarchy by suggesting an alternative cancer stem cell population critical for disease progression.

Expanding on these findings, the DKFZ researchers conducted rigorous experiments involving patient-derived organoids—miniature, lab-grown versions of tumors—and mouse xenograft models. These platforms illuminated the selective vulnerability of TROP2-high cancer clones to antibody-drug conjugates designed to deliver cytotoxic agents directly to TROP2-positive cells. Such targeted therapeutics have demonstrated clinical success in breast cancer, and their repurposing in colorectal cancer reflects a promising therapeutic pivot exploiting tumor biology.

A particularly novel insight from the study was the observed effect of standard chemotherapeutics on TROP2 expression dynamics. Conventional treatments were found to inadvertently enrich the TROP2-positive subpopulation within tumors, presumably by eliminating more differentiated cancer cells and allowing the resilient, plastic cells to thrive. Rather than viewing this as a setback, the researchers conceptualized a dual-therapy strategy: first, employing chemotherapy to increase the density of TROP2-positive cells, followed by administering TROP2-targeted agents to effectively eradicate this dangerous cohort.

Experimental validation of this combination approach yielded remarkable outcomes. The concerted treatment protocols displayed superior efficacy, substantially suppressing tumor growth and metastasis compared to monotherapies. Mouse models receiving the dual therapy experienced prolonged survival, underscoring the translational potential of this strategy. These findings advocate a paradigm shift where tumor plasticity, once deemed a barrier, is tactically subverted to amplify therapeutic impact.

The implications of this research extend beyond therapy to diagnostics. TROP2’s capacity to serve as both a marker of aggressive disease and a therapeutic target offers clinicians a dual advantage in stratifying patients and tailoring intervention regimens. Early identification of high TROP2 expression tumors could refine prognostic assessments and guide enrollment in trials evaluating TROP2-directed agents, thereby personalizing treatment avenues.

Moreover, since TROP2-targeting drugs have already secured regulatory approval for use in other malignancies, the path to clinical implementation in colorectal cancer is significantly expedited. The DKFZ team is actively collaborating with Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) Heidelberg to advance the antibody-drug conjugate into Phase 2/3 clinical trials for patients with advanced disease, aiming to corroborate preclinical successes in a therapeutic setting.

This study epitomizes an integrative approach, combining cutting-edge molecular profiling, sophisticated preclinical models, and clinical insights to unravel the complexity of cancer cell states driving metastasis and resistance. By harnessing the plasticity of tumor cells as a therapeutic vulnerability, the research sets a new benchmark for innovation in precision oncology, particularly for colorectal cancer where unmet medical needs persist.

In summary, the discovery of TROP2 as a hallmark of metastatic colorectal cancer cells, along with the practical demonstration of effective, clinically applicable treatments, charts a transformative course in cancer medicine. It signals hope for improved survival outcomes through refined biomarker-driven therapies that decisively target the roots of tumor aggressiveness and therapeutic failure.

*The Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) gGmbH was established in 2008 as a collaborative initiative between the German Cancer Research Center and the Dietmar Hopp Foundation.

News Publication Date: 2026

Web References: DOI: 10.1038/s41586-026-10705-2

References: Vaquero-Siguero et al., Nature, 2026